表紙
市場調査レポート

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン分析

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 237879
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン分析 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 108 Pages
概要

特発性血小板減少性紫斑病(ITP)は、血小板数が減少し、出血しやすくなる疾患です。この疾患の症状には、 切り傷からの出血が止まりにくい、鼻からの突発的な出血、血尿や血便、歯茎からの出血、倦怠感などがあります。ITPの代表的な治療法には、副腎皮質ホルモン(コルチコステロイド)や免疫抑制剤の投与があります。

当レポートでは、世界においてパイプライン中にある特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)治療薬の概要を提供しており、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):企業で開発中の治療薬

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):大学/機関で研究中の治療薬

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):企業で開発中の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):大学/機関で研究中の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)の治療薬開発に従事している企業

  • 3SBio Inc.
  • Amgen Inc.
  • Baxalta Incorporated
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • エーザイ
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 自己免疫疾患・炎症向け阻害剤
  • avatrombopag
  • BI-655064
  • BMS-986004
  • eltrombopag olamine
  • eltrombopag olamine
  • fostamatinib disodium
  • GL-2045
  • GSK-2285921
  • Hetrombopag Olamine
  • MK-8723
  • PBF-1509
  • PHN-013
  • PRTX-100
  • 自己免疫疾患向け免疫グロビンG阻害組み換え酵素
  • romiplostim
  • romiplostim のバイオシミラー
  • SM-101
  • thrombopoietin
  • veltuzumab

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):最近のパイプライン動向

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):休止中のプロジェクト

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):開発が中止された製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8392IDB

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
  • The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
  • The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 7
  • Introduction 8
  • Global Markets Direct Report Coverage 8
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 9
  • Therapeutics Development 10
  • Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 10
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13
  • Late Stage Products 13
  • Clinical Stage Products 14
  • Early Stage Products 15
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 18
  • 3SBio Inc. 18
  • AkaRx Inc 19
  • Amgen Inc. 20
  • arGEN-X BV 21
  • Boehringer Ingelheim GmbH 22
  • Bristol-Myers Squibb Company 23
  • Genosco 24
  • Hansa Medical AB 25
  • Immunomedics, Inc. 26
  • Intas Pharmaceuticals Ltd. 27
  • Jiangsu Hengrui Medicine Co., Ltd. 28
  • Merck & Co., Inc. 29
  • Momenta Pharmaceuticals, Inc. 30
  • Novartis AG 31
  • Pfizer Inc. 32
  • PhytoHealth Corporation 33
  • Protalex, Inc. 34
  • Rigel Pharmaceuticals, Inc. 35
  • Shire Plc 36
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 37
  • Assessment by Monotherapy Products 37
  • Assessment by Target 38
  • Assessment by Mechanism of Action 40
  • Assessment by Route of Administration 42
  • Assessment by Molecule Type 44
  • Drug Profiles 46
  • Antibody for Autoimmune Disorders and Inflammation - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • ARGX-113 - Drug Profile 47
  • Product Description 47
  • Mechanism Of Action 47
  • R&D Progress 47
  • avatrombopag - Drug Profile 49
  • Product Description 49
  • Mechanism Of Action 49
  • R&D Progress 49
  • BI-655064 - Drug Profile 51
  • Product Description 51
  • Mechanism Of Action 51
  • R&D Progress 51
  • BMS-986004 - Drug Profile 53
  • Product Description 53
  • Mechanism Of Action 53
  • R&D Progress 53
  • eltrombopag olamine - Drug Profile 54
  • Product Description 54
  • Mechanism Of Action 54
  • R&D Progress 54
  • eltrombopag olamine - Drug Profile 60
  • Product Description 60
  • Mechanism Of Action 60
  • R&D Progress 60
  • fostamatinib disodium - Drug Profile 61
  • Product Description 61
  • Mechanism Of Action 61
  • R&D Progress 61
  • GL-2045 - Drug Profile 66
  • Product Description 66
  • Mechanism Of Action 66
  • R&D Progress 66
  • GSK-2285921 - Drug Profile 67
  • Product Description 67
  • Mechanism Of Action 67
  • R&D Progress 67
  • Hetrombopag Olamine - Drug Profile 69
  • Product Description 69
  • Mechanism Of Action 69
  • R&D Progress 69
  • M-281 - Drug Profile 70
  • Product Description 70
  • Mechanism Of Action 70
  • R&D Progress 70
  • MK-8723 - Drug Profile 71
  • Product Description 71
  • Mechanism Of Action 71
  • R&D Progress 71
  • PHN-013 - Drug Profile 72
  • Product Description 72
  • Mechanism Of Action 72
  • R&D Progress 72
  • PRTX-100 - Drug Profile 73
  • Product Description 73
  • Mechanism Of Action 73
  • R&D Progress 73
  • Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 80
  • Product Description 80
  • Mechanism Of Action 80
  • R&D Progress 80
  • romiplostim - Drug Profile 81
  • Product Description 81
  • Mechanism Of Action 81
  • R&D Progress 81
  • romiplostim biosimilar - Drug Profile 84
  • Product Description 84
  • Mechanism Of Action 84
  • R&D Progress 84
  • SKIO-703 - Drug Profile 85
  • Product Description 85
  • Mechanism Of Action 85
  • R&D Progress 85
  • SM-101 - Drug Profile 86
  • Product Description 86
  • Mechanism Of Action 86
  • R&D Progress 86
  • thrombopoietin - Drug Profile 89
  • Product Description 89
  • Mechanism Of Action 89
  • R&D Progress 89
  • veltuzumab - Drug Profile 90
  • Product Description 90
  • Mechanism Of Action 90
  • R&D Progress 90
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 94
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 95
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 96
  • Featured News & Press Releases 96
  • Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder 96
  • May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association 97
  • Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP 98
  • Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 99
  • Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 100
  • Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 100
  • Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 101
  • Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 102
  • Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 102
  • Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 103
  • Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 104
  • Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 104
  • Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 105
  • Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 105
  • Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 105
  • Appendix 107
  • Methodology 107
  • Coverage 107
  • Secondary Research 107
  • Primary Research 107
  • Expert Panel Validation 107
  • Contact Us 107
  • Disclaimer 108

List of Tables

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016 10
  • Number of Products under Development by Companies, H2 2016 12
  • Comparative Analysis by Late Stage Development, H2 2016 13
  • Comparative Analysis by Clinical Stage Development, H2 2016 14
  • Comparative Analysis by Early Stage Development, H2 2016 15
  • Products under Development by Companies, H2 2016 16
  • Products under Development by Companies, H2 2016 (Contd..1) 17
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H2 2016 18
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by AkaRx Inc, H2 2016 19
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H2 2016 20
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2016 21
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 22
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2016 23
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco, H2 2016 24
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2016 25
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H2 2016 26
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 27
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 28
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H2 2016 29
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 30
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2016 31
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H2 2016 32
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H2 2016 33
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H2 2016 34
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 35
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shire Plc, H2 2016 36
  • Assessment by Monotherapy Products, H2 2016 37
  • Number of Products by Stage and Target, H2 2016 39
  • Number of Products by Stage and Mechanism of Action, H2 2016 41
  • Number of Products by Stage and Route of Administration, H2 2016 43
  • Number of Products by Stage and Molecule Type, H2 2016 45
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2016 94
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2016 95

List of Figures

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016 10
  • Number of Products under Development by Companies, H2 2016 11
  • Comparative Analysis by Late Stage Development, H2 2016 13
  • Comparative Analysis by Clinical Stage Development, H2 2016 14
  • Comparative Analysis by Early Stage Products, H2 2016 15
  • Assessment by Monotherapy Products, H2 2016 37
  • Number of Products by Targets, H2 2016 38
  • Number of Products by Stage and Targets, H2 2016 38
  • Number of Products by Mechanism of Actions, H2 2016 40
  • Number of Products by Stage and Mechanism of Actions, H2 2016 40
  • Number of Products by Routes of Administration, H2 2016 42
  • Number of Products by Stage and Routes of Administration, H2 2016 42
  • Number of Products by Molecule Types, H2 2016 44
  • Number of Products by Stage and Molecule Types, H2 2016 44
Back to Top